NovaBiotics are delighted to announce that our CARE CF 1 phase 2b clinical trial data for oral Lynovex in infectious pulmonary exacerbations of cystic fibrosis is published today in PLOS ONE. Our findings further support the potential of Lynovex® as game-changer in CF therapy.
Our Lynovex infographic summarises the properties of Lynovex and the PLOS ONE research article is available here PLOS CARE CF 1 Research article